Cato BioVentures is the venture capital affiliate of Cato Holding, a privately held family fund. For 30 years Cato BioVentures has partnered with entrepreneurs, academic institutions, and a broad base of biotech and pharmaceutical companies to advance a robust portfolio of successful product development programs. Cato BioVentures has invested in innovative therapeutics, medical devices and stem cell technologies that improve Pharma's Research and Development productivity.
We invest in opportunities at all stages of development and across multiple therapeutic areas in both private and public companies. Our goal at Cato BioVentures is to partner with our portfolio companies to make a difference in the successful outcome of your core development programs.
Cato BioVentures invests only in opportunities where we can make a difference in development or regulatory strategy. We often co-invest with other institutional investors and generally we do not require a Board seat as a condition of our investment. Still, in a Board-like manner, our principals regularly provide essential market, regulatory and drug development insights, as well as financial, operational and strategic advice, to portfolio company management through regular and uncompensated communications. We are long-term investors who can assist our portfolio companies with product development - including clinical development, regulatory affairs, manufacturing, government and private foundation grant-writing - and corporate development - including corporate finance, strategic planning and corporate partnering.
We value the opportunity to work closely with management in multiple areas to build value in our portfolio partners' drug or technology development opportunities. Typically, we deploy the collective development and regulatory expertise of our principals and the entire 300+ person CRO staff of Cato Research to achieve maximum value for our partners. Drug development, including preclinical studies, clinical studies, manufacturing, and regulatory affairs, have been the core components of the business of Cato Research for over 30 years.
We seek to invest in companies with a reasonable business model built on innovative drug candidates or technologies supported by a strong intellectual property position and a solid pathway to commercialization.